Uprosertib - Laekna Therapeutics
Alternative Names: GSK-2141795; GSK-2141795C; GSK-795; LAE 003; UPB 795Latest Information Update: 22 Jun 2024
At a glance
- Originator GlaxoSmithKline
- Developer Dana-Farber Cancer Institute; Laekna Therapeutics; National Cancer Institute (USA); National Comprehensive Cancer Network; Novartis Oncology; University of California at San Francisco
- Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hereditary haemorrhagic telangiectasia; Proteus syndrome
- Discontinued Acute myeloid leukaemia; Cervical cancer; Endometrial cancer; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Solid tumours; Triple negative breast cancer; Uveal melanoma
Most Recent Events
- 05 Apr 2024 Efficacy and pharmacodynamics data from a phase II trial in Triple-negative-breast-cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Sep 2022 Uprosertib - Laekna Therapeutics is available for licensing as of 14 Sep 2022. https://en.laekna.com/ (Laekna Therapeutics pipeline, September 2022)
- 14 Sep 2022 Discontinued - Phase-II for Malignant melanoma (Combination therapy) in USA (PO) (Laekna Therapeutics pipeline, September 2022)